Trial Profile

Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib (Primary) ; Diclofenac; Omeprazole
Indications Musculoskeletal pain; NSAID-induced gastrointestinal damage; Osteoarthritis; Rheumatoid arthritis
Focus Adverse reactions
Acronyms CONDOR
Sponsors Pfizer; Viatris Inc

18 Jun 2010 Results of this trial will be presented at the 2010 Annual European Congress of Rheumatology (EULAR), according to a Pfizer media release.
18 Jun 2010 Results of this trial have been published in the Lancet, according to a Pfizer media release.
17 Jun 2010 Results presented at the 11th Annual Congress of the European League Against Rheumatism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com